中国肺癌杂志
中國肺癌雜誌
중국폐암잡지
Chinese Journal of Lung Cancer
2015年
9期
554-558
,共5页
许建萍%刘潇衍%杨晟%张湘茹%石远凯
許建萍%劉瀟衍%楊晟%張湘茹%石遠凱
허건평%류소연%양성%장상여%석원개
吉非替尼%肺肿瘤%脑转移
吉非替尼%肺腫瘤%腦轉移
길비체니%폐종류%뇌전이
Geiftinib%Lung neoplasms%Brain metastasis
背景与目的脑转移是晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）常见的转移部位，预后欠佳。吉非替尼是一种表皮生长因子受体（epithelial growth factor receptor, EGFR）酪氨酸激酶抑制剂，用于治疗晚期NSCLC。本研究旨在探讨吉非替尼治疗肺腺癌脑转移的疗效及毒副反应。方法回顾性分析32例肺腺癌脑转移患者的临床资料，所有患者均口服吉非替尼250 mg Qd，直到疾病进展或发生不可耐受的毒副反应。结果全组32例患者的中位生存时间（median overall survival, mOS）和中位无进展生存时间（median progression-free survival, mPFS）分别为24.7个月和11.2个月，有效率（response rate, RR）和疾病控制率（disease control rate, DCR）分别为62.5%和93.8%。吉非替尼用于初治患者的mOS和mPFS分别为35.6个月和11.3个月，RR和DCR分别为75.0%和100.0%。吉非替尼用于复治患者的mOS和mPFS分别为18.6个月和6.7个月，RR和DCR分别为50.0%和83.3%。EGFR敏感性突变患者的mOS和mPFS分别为24.8个月和10.8个月，RR和DCR分别为75.0%和100.0%。EGFR突变状态不明患者的mOS和mPFS分别为35.6个月和12.3个月，RR和DCR分别为53.3%和86.7%。全组患者耐受性好，未观察到严重毒副反应。常见的毒副反应包括：皮疹15例（46.9%）、腹泻7例（21.9%）、口腔溃疡1例（3.1%）。结论吉非替尼对肺腺癌脑转移患者有效率较高且耐受性好，可以作为肺腺癌脑转移患者的一种治疗选择。
揹景與目的腦轉移是晚期非小細胞肺癌（non-small cell lung cancer, NSCLC）常見的轉移部位，預後欠佳。吉非替尼是一種錶皮生長因子受體（epithelial growth factor receptor, EGFR）酪氨痠激酶抑製劑，用于治療晚期NSCLC。本研究旨在探討吉非替尼治療肺腺癌腦轉移的療效及毒副反應。方法迴顧性分析32例肺腺癌腦轉移患者的臨床資料，所有患者均口服吉非替尼250 mg Qd，直到疾病進展或髮生不可耐受的毒副反應。結果全組32例患者的中位生存時間（median overall survival, mOS）和中位無進展生存時間（median progression-free survival, mPFS）分彆為24.7箇月和11.2箇月，有效率（response rate, RR）和疾病控製率（disease control rate, DCR）分彆為62.5%和93.8%。吉非替尼用于初治患者的mOS和mPFS分彆為35.6箇月和11.3箇月，RR和DCR分彆為75.0%和100.0%。吉非替尼用于複治患者的mOS和mPFS分彆為18.6箇月和6.7箇月，RR和DCR分彆為50.0%和83.3%。EGFR敏感性突變患者的mOS和mPFS分彆為24.8箇月和10.8箇月，RR和DCR分彆為75.0%和100.0%。EGFR突變狀態不明患者的mOS和mPFS分彆為35.6箇月和12.3箇月，RR和DCR分彆為53.3%和86.7%。全組患者耐受性好，未觀察到嚴重毒副反應。常見的毒副反應包括：皮疹15例（46.9%）、腹瀉7例（21.9%）、口腔潰瘍1例（3.1%）。結論吉非替尼對肺腺癌腦轉移患者有效率較高且耐受性好，可以作為肺腺癌腦轉移患者的一種治療選擇。
배경여목적뇌전이시만기비소세포폐암（non-small cell lung cancer, NSCLC）상견적전이부위，예후흠가。길비체니시일충표피생장인자수체（epithelial growth factor receptor, EGFR）락안산격매억제제，용우치료만기NSCLC。본연구지재탐토길비체니치료폐선암뇌전이적료효급독부반응。방법회고성분석32례폐선암뇌전이환자적림상자료，소유환자균구복길비체니250 mg Qd，직도질병진전혹발생불가내수적독부반응。결과전조32례환자적중위생존시간（median overall survival, mOS）화중위무진전생존시간（median progression-free survival, mPFS）분별위24.7개월화11.2개월，유효솔（response rate, RR）화질병공제솔（disease control rate, DCR）분별위62.5%화93.8%。길비체니용우초치환자적mOS화mPFS분별위35.6개월화11.3개월，RR화DCR분별위75.0%화100.0%。길비체니용우복치환자적mOS화mPFS분별위18.6개월화6.7개월，RR화DCR분별위50.0%화83.3%。EGFR민감성돌변환자적mOS화mPFS분별위24.8개월화10.8개월，RR화DCR분별위75.0%화100.0%。EGFR돌변상태불명환자적mOS화mPFS분별위35.6개월화12.3개월，RR화DCR분별위53.3%화86.7%。전조환자내수성호，미관찰도엄중독부반응。상견적독부반응포괄：피진15례（46.9%）、복사7례（21.9%）、구강궤양1례（3.1%）。결론길비체니대폐선암뇌전이환자유효솔교고차내수성호，가이작위폐선암뇌전이환자적일충치료선택。
Background and objective Brain metastasis was frequent in non-small cell lung cancer (NSCLC) patients with poor prognosis. Geiftinib was an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has been used in the treatment of NSCLC. Our study was to evaluate the effcacy and toxicities of geiftinib in lung adenocarcinoma patients with brain metastases. Methods We retrospectively reviewed clinical records of 32 lung adenocarcinoma patients with brain metastases, who had received geiftinib 250 mg Qd until disease progression or intolerable toxicities. Results hTe median overall survival (mOS) and median progression-free survival (mPFS) were 24.7 months and 11.2 months, respectively. Response rate (RR) and disease control rate (DCR) were 62.5%and 93.8%, respectively. hTe mOS and mPFS of geiftinib-naive patients were 35.6 months and 11.3 months, respectively, and RR and DCR were 75.0%and 100.0%, respectively. hTe mOS and mPFS of geiftinib treatment patients were 18.6 months and 6.7 months, respectively, and RR and DCR were 50.0%and 83.3%, respectively. hTe mOS and mPFS of patients with sensitive EGFR mutation were 24.8 months and 10.8 months, respectively, and RR and DCR were 75.0%and 100.0%, respectively. hTe mOS and mPFS of patients with unknown EGFR status were 35.6 months and 12.3 months, respectively, and RR and DCR were 53.3%and 86.7%, respectively. Treatment was well tolerated and no severe toxicities were observed. Common toxicities include:rash in 15 patients (46.9%), diarrhea in 7 cases (21.9%) and oral ulcer in 1 case (3.1%). Conclusion Geiftinib was highly effective and well tolerated in lung adenocarcinoma patients with brain metastases, and could be recommended as a treatment choice for this population.
